No Data
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)
LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Rockwell Med (RMTI) and Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics GAAP EPS of -$0.49
Inhibikase Therapeutics | 10-K: FY2025 Annual Report
1015282 : promoting!!